Dual kinase inhibitor for EGFR mutants and ErbB2 limit breast cancer
- 9 February 2023
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 651, 39-46
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01CA219034, R21AI35359)
- Breast Cancer Research Foundation (BCRF-17-061)
- Magyar Tüdőgyógyász Társaság (33,34)
This publication has 32 references indexed in Scilit:
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer CellsPLOS ONE, 2008
- ErbB receptors: from oncogenes to targeted cancer therapiesJournal of Clinical Investigation, 2007
- Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase InhibitorsClinical Cancer Research, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic MiceClinical Cancer Research, 2004
- LIGPLOT: a program to generate schematic diagrams of protein-ligand interactionsProtein Engineering, Design and Selection, 1995
- erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 CellsScience, 1987